Literature DB >> 9789022

Inhibiting transthyretin conformational changes that lead to amyloid fibril formation.

S A Peterson1, T Klabunde, H A Lashuel, H Purkey, J C Sacchettini, J W Kelly.   

Abstract

Insoluble protein fibrils resulting from the self-assembly of a conformational intermediate are implicated as the causative agent in several severe human amyloid diseases, including Alzheimer's disease, familial amyloid polyneuropathy, and senile systemic amyloidosis. The latter two diseases are associated with transthyretin (TTR) amyloid fibrils, which appear to form in the acidic partial denaturing environment of the lysosome. Here we demonstrate that flufenamic acid (Flu) inhibits the conformational changes of TTR associated with amyloid fibril formation. The crystal structure of TTR complexed with Flu demonstrates that Flu mediates intersubunit hydrophobic interactions and intersubunit hydrogen bonds that stabilize the normal tetrameric fold of TTR. A small-molecule inhibitor that stabilizes the normal conformation of a protein is desirable as a possible approach to treat amyloid diseases. Molecules such as Flu also provide the means to rigorously test the amyloid hypothesis, i.e., the apparent causative role of amyloid fibrils in amyloid disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9789022      PMCID: PMC23669          DOI: 10.1073/pnas.95.22.12956

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

Review 1.  Genetic aspects of amyloidosis.

Authors:  D R Jacobson; J N Buxbaum
Journal:  Adv Hum Genet       Date:  1991

Review 2.  Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases.

Authors:  J W Kelly
Journal:  Structure       Date:  1997-05-15       Impact factor: 5.006

3.  Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.

Authors:  D R Jacobson; R D Pastore; R Yaghoubian; I Kane; G Gallo; F S Buck; J N Buxbaum
Journal:  N Engl J Med       Date:  1997-02-13       Impact factor: 91.245

4.  Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein.

Authors:  H L Monaco; M Rizzi; A Coda
Journal:  Science       Date:  1995-05-19       Impact factor: 47.728

5.  Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A.

Authors:  C C Blake; M J Geisow; S J Oatley; B Rérat; C Rérat
Journal:  J Mol Biol       Date:  1978-05-25       Impact factor: 5.469

6.  Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo.

Authors:  E Scherzinger; R Lurz; M Turmaine; L Mangiarini; B Hollenbach; R Hasenbank; G P Bates; S W Davies; H Lehrach; E E Wanker
Journal:  Cell       Date:  1997-08-08       Impact factor: 41.582

7.  Fibrillar islet amyloid polypeptide (amylin) is internalised by macrophages but resists proteolytic degradation.

Authors:  M K Badman; R A Pryce; S B Chargé; J F Morris; A Clark
Journal:  Cell Tissue Res       Date:  1998-02       Impact factor: 5.249

8.  Studies on thyroid hormone-binding proteins. II. Binding of thyroid hormones, retinol-binding protein, and fluorescent probes to prealbumin and effects of thyroxine on prealbumin subunit self association.

Authors:  S F Nilsson; L Rask; P A Peterson
Journal:  J Biol Chem       Date:  1975-11-10       Impact factor: 5.157

9.  Discovering transthyretin amyloid fibril inhibitors by limited screening.

Authors:  P W Baures; S A Peterson; J W Kelly
Journal:  Bioorg Med Chem       Date:  1998-08       Impact factor: 3.641

10.  The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.

Authors:  Z Lai; W Colón; J W Kelly
Journal:  Biochemistry       Date:  1996-05-21       Impact factor: 3.162

View more
  45 in total

1.  Formation of amyloid fibrils by peptides derived from the bacterial cold shock protein CspB.

Authors:  M Gross; D K Wilkins; M C Pitkeathly; E W Chung; C Higham; A Clark; C M Dobson
Journal:  Protein Sci       Date:  1999-06       Impact factor: 6.725

2.  A possible therapeutic target for Lou Gehrig's disease.

Authors:  Soumya S Ray; Peter T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

3.  Characterization of a possible amyloidogenic precursor in glutamine-repeat neurodegenerative diseases.

Authors:  Roger S Armen; Brady M Bernard; Ryan Day; Darwin O V Alonso; Valerie Daggett
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-12       Impact factor: 11.205

4.  Leptomeningeal familial amyloidosis: A rare differential diagnosis of leptomeningeal enhancement in MRI.

Authors:  P P Urban; C Hertkorn; J M Schattenberg; J Gawehn; S Hägele; M Wunsch; K Altland
Journal:  J Neurol       Date:  2006-09-21       Impact factor: 4.849

5.  A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.

Authors:  Sungwook Choi; Natàlia Reixach; Stephen Connelly; Steven M Johnson; Ian A Wilson; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2010-02-03       Impact factor: 15.419

6.  A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.

Authors:  Sungwook Choi; Jeffery W Kelly
Journal:  Bioorg Med Chem       Date:  2010-12-30       Impact factor: 3.641

7.  Aromatic sulfonyl fluorides covalently kinetically stabilize transthyretin to prevent amyloidogenesis while affording a fluorescent conjugate.

Authors:  Neil P Grimster; Stephen Connelly; Aleksandra Baranczak; Jiajia Dong; Larissa B Krasnova; K Barry Sharpless; Evan T Powers; Ian A Wilson; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2013-02-14       Impact factor: 15.419

Review 8.  Current and future treatment of amyloid diseases.

Authors:  M Ankarcrona; B Winblad; C Monteiro; C Fearns; E T Powers; J Johansson; G T Westermark; J Presto; B-G Ericzon; J W Kelly
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

9.  Novel transthyretin amyloid fibril formation inhibitors: synthesis, biological evaluation, and X-ray structural analysis.

Authors:  Satheesh K Palaninathan; Nilofar N Mohamedmohaideen; Elisabetta Orlandini; Gabriella Ortore; Susanna Nencetti; Annalina Lapucci; Armando Rossello; Joel S Freundlich; James C Sacchettini
Journal:  PLoS One       Date:  2009-07-21       Impact factor: 3.240

10.  Transgenic fat-1 mouse as a model to study the pathophysiology of cardiovascular, neurological and psychiatric disorders.

Authors:  Undurti N Das; László G Puskás
Journal:  Lipids Health Dis       Date:  2009-12-30       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.